193 related articles for article (PubMed ID: 23860970)
21. Critics press FDA to act on evidence of rosiglitazone's cardiac safety issues.
Mitka M
JAMA; 2010 Jun; 303(23):2341-2. PubMed ID: 20551399
[No Abstract] [Full Text] [Related]
22. Rosiglitazone and cardiovascular disease: a cardiologist's perspective.
Marx N
Diab Vasc Dis Res; 2007 Jun; 4(2):80-1. PubMed ID: 17654439
[No Abstract] [Full Text] [Related]
23. Rosiglitazone and the FDA.
Joffe HV; Parks MH; Meyer RJ; Jenkins JK; Temple R
N Engl J Med; 2007 Oct; 357(17):1775-6; author reply 1777. PubMed ID: 17761586
[No Abstract] [Full Text] [Related]
24. The safety of rosiglitazone in the treatment of type 2 diabetes.
Singh S; Loke YK
Expert Opin Drug Saf; 2008 Sep; 7(5):579-85. PubMed ID: 18759710
[TBL] [Abstract][Full Text] [Related]
25. Rosiglitazone: seeking a balanced perspective.
The Lancet
Lancet; 2007 Jun; 369(9576):1834. PubMed ID: 17544746
[No Abstract] [Full Text] [Related]
26. [Uncertainly after publications on glitazones. Elevated myocardial infarction risk is not a class effect].
Erdmann E; Scherbaum WA
MMW Fortschr Med; 2007 Dec; 149(49-50):49-50. PubMed ID: 18236983
[No Abstract] [Full Text] [Related]
27. FDA committee urges tight restrictions on rosiglitazone.
Roehr B
BMJ; 2010 Jul; 341():c3862. PubMed ID: 20639290
[No Abstract] [Full Text] [Related]
28. Regulatory action on rosiglitazone by the U.S. Food and Drug Administration.
Woodcock J; Sharfstein JM; Hamburg M
N Engl J Med; 2010 Oct; 363(16):1489-91. PubMed ID: 20942663
[No Abstract] [Full Text] [Related]
29. Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation.
Kaul S; Bolger AF; Herrington D; Giugliano RP; Eckel RH
Circulation; 2010 Apr; 121(16):1868-77. PubMed ID: 20179252
[No Abstract] [Full Text] [Related]
30. The record on rosiglitazone and the risk of myocardial infarction.
Psaty BM; Furberg CD
N Engl J Med; 2007 Jul; 357(1):67-9. PubMed ID: 17551162
[No Abstract] [Full Text] [Related]
31. Rosiglitazone: failure of oversight or demons imagined?
Susman J
J Fam Pract; 2007 Sep; 56(9):696, 703. PubMed ID: 17764640
[No Abstract] [Full Text] [Related]
32. Responding to an FDA warning--geographic variation in the use of rosiglitazone.
Shah ND; Montori VM; Krumholz HM; Tu K; Alexander GC; Jackevicius CA
N Engl J Med; 2010 Nov; 363(22):2081-4. PubMed ID: 21083379
[No Abstract] [Full Text] [Related]
33. A perspective on the American Heart Association/American College of Cardiology science advisory on thiazolidinedione drugs and cardiovascular risks.
Krumholz HM
Circ Cardiovasc Qual Outcomes; 2010 May; 3(3):221-2. PubMed ID: 20181986
[No Abstract] [Full Text] [Related]
34. The long Avandia endgame.
Mullard A
Lancet; 2011 Jul; 378(9786):113. PubMed ID: 21748869
[No Abstract] [Full Text] [Related]
35. Avandia outcome may signal change in epidemiologists' sway.
Wadman M
Nat Med; 2010 Jun; 16(6):614. PubMed ID: 20526293
[No Abstract] [Full Text] [Related]
36. The rosiglitazone meta-analysis.
McCullough PA; Lepor NE
Rev Cardiovasc Med; 2007; 8(2):123-6. PubMed ID: 17603430
[No Abstract] [Full Text] [Related]
37. Review article: Thiazolidinediones and heart failure.
Chaggar PS; Shaw SM; Williams SG
Diab Vasc Dis Res; 2009 Jul; 6(3):146-52. PubMed ID: 20368206
[TBL] [Abstract][Full Text] [Related]
38. FDA eases restrictions on the glucose-lowering drug rosiglitazone.
Mitka M
JAMA; 2013 Dec; 310(24):2604. PubMed ID: 24368444
[No Abstract] [Full Text] [Related]
39. Thiazolidinediones, deadly sins, surrogates, and elephants.
Cleland JG; Atkin SL
Lancet; 2007 Sep; 370(9593):1103-4. PubMed ID: 17905146
[No Abstract] [Full Text] [Related]
40. Studies of diabetes, thiazolidinediones, and coronary heart disease.
Walker AM; McAfee AT; Koro C
Pharmacoepidemiol Drug Saf; 2007 Dec; 16(12):1313-4; author reply 1314-6. PubMed ID: 18041104
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
